CSIMarket


Beam Therapeutics Inc   (BEAM)
Other Ticker:  
 


 

Beam Therapeutics Inc

BEAM's Financial Statements and Analysis



Beam Therapeutics Inc increased second quarter of 2023 net loss per share of $-1.08 compare to net loss per share of $-1.02 recorded in the same quarter a year ago and improved compare to net loss per share of $-1.33 realized in previous quarter.


second quarter of 2023
Earnings Per Share Revenues
$ -1.08 $  20 Mill
$-0.06     $+3M     +20.8 %



Beam Therapeutics Inc 's Revenue rose by 20.8 % in second quarter of 2023 (Jun 30 2023) year on year, to $20 million and declined by -16.9 % sequentially.


Beam Therapeutics Inc is Expected to report next financial results on November 06, 2023.

More on BEAM's Income Statement



Beam Therapeutics Inc 's in thesecond quarter of 2023 recorded net loss of $-82.776 million, an increase from net loss of $-71.950 million in II. Quarter a year ago.

Sequentially net loss narrowed from net loss of $-96.460 million realized in previous quarter.

More on BEAM's Growth

Beam Therapeutics Inc Inventories
In Jun 30 2023 company's net cash and cash equivalents decreased by $-19 million, capital expenditures grew by -25.25%, to $-16 millions compare to same quarter a year ago and fell by 168.87% from I. Quarter (Mar 31 2023).

More on BEAM's Cash flow Statement


Beam Therapeutics Inc does not pay out common stock dividend.

In trailing twelve-month period Beam Therapeutics Inc payed $ -4.43 cash per share, on a free-cash flow basis .

Book value grew by 0.91 % sequentially to $10.63 per share.
Tangible Book value grew to $ 10.63 per share from $ 10.54.

Company issued 4.06 million shares or 5.62 % in Jun 30 2023.


More on BEAM's Dividends

 Market Capitalization (Millions) 1,836
 Shares Outstanding (Millions) 76
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) 80
 Net Income (TTM) (Millions $) -327
 Cash Flow (TTM) (Millions $) -37
 Capital Exp. (TTM) (Millions $) -42
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 3,400




Beam Therapeutics Inc does not pay out common stock dividend.

In trailing twelve-month period Beam Therapeutics Inc had negative $ -4.43 cash flow per share, on a free-cash flow basis .

Book value grew by 0.91 % sequentially to $10.63 per share.
Tangible Book value grew to $ 10.63 per share from $ 10.54.

Company issued 4.06 million shares or 5.62 % in Jun 30 2023.


More on BEAM's Balance Sheets

 Market Capitalization (Millions) 1,836
 Shares Outstanding (Millions) 76
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) 80
 Net Income (TTM) (Millions $) -327
 Cash Flow (TTM) (Millions $) -37
 Capital Exp. (TTM) (Millions $) -42
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 3,400
   


Date modified: 2023-08-08T17:16:48+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com